Biotech company Alvotech S.A. (NASDAQ:ALVO) announced on Tuesday an agreement with German pharmaceutical company STADA Arzneimittel AG (FWB:SAZ) to form a broader biosimilar partnership.
Under the new agreement STADA gets marketing rights for Alvotech's AVT03, a clinical-stage biosimilar candidate referencing Prolia/Xgeva (denosumab), in Europe and parts of Central Asia and the Middle East. This builds on their existing alliance for biosimilars.
Alvotech will develop and manufacture AVT03, targeting osteoporosis and cancer-related bone loss. Upon approval, STADA will commercialise it in specified territories.
The agreement also expands STADA's commercial rights to existing Alvotech biosimilars in Central Asia, while Alvotech will regain commercial rights from STADA to AVT06, a proposed biosimilar to Eylea (aflibercept).
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
Telix Pharmaceuticals' Illuccix receives UK regulatory approval
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
AbbVie and Xilio Therapeutics announce collaboration to develop tumour-activated immunotherapies
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline